Cancer Therapy with Immune Checkpoint Inhibitors – the Hidden Targets
2The Wohl Institute for Translational Medicine, Hadassah Hebrew University Medical Center, Israel
3Lautenberg Institute of Immunology and Cancer Research, Hadassah Hebrew University Faculty of Medicine, Israel
4MD/PhD Program, Hadassah Hebrew University Faculty of Medicine, Israel
5Department of Biochemistry and Molecular Biology, Hadassah Hebrew University Faculty of Medicine, Israel
Clinical sample analyses with high-resolution transcriptomic yield a list of immune modulators which are associated with response and resistance to cancer immunotherapy. While indicating potential treatment targets, the data ignores biomolecules that do not clearly cluster with a particular prophetic molecular signatures. Thus, a plethora of modulatory receptors is overlooked, which could have been potential treatment targets. In this talk emphasis will be given to alternative splicing of immune receptors as a source of diversity in their net immune effect on lymphocytes and anti-cancer response. The example of the SLAM family member 6 will be used to exemplify the role of splicing in immune modulation and the potential of splicing manipulation to augment immune response.
Alternative splicing of immune receptor generates unrecognized sequences that can be used for treatment or can be targeted by oligonucleotides as a new avenue of cancer treatment
Powered by Eventact EMS